These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14687613)

  • 1. Comparative gene expression profile of p185(Bcr-Abl) versus p210(Bcr-Abl) expressing cells.
    Tipping AJ; Melo JV
    Leuk Res; 2004 Mar; 28(3):219-20. PubMed ID: 14687613
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
    Advani AS; Dressman HK; Quiroz M; Taylor GA; Pendergast AM
    Leuk Res; 2004 Mar; 28(3):285-94. PubMed ID: 14687624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
    Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
    Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210
    Vinhas R; Lourenço A; Santos S; Ribeiro P; Silva M; de Sousa AB; Baptista PV; Fernandes AR
    Haematologica; 2018 Nov; 103(11):e549-e552. PubMed ID: 30093395
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
    Quackenbush RC; Reuther GW; Miller JP; Courtney KD; Pear WS; Pendergast AM
    Blood; 2000 May; 95(9):2913-21. PubMed ID: 10779439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
    Mian AA; Metodieva A; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
    Haematologica; 2012 Feb; 97(2):251-7. PubMed ID: 22058195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of bcr/abl fusion gene on expression of beta1 integrin and L-selectin in mouse chronic myeloid leukemia cells].
    Wang WL; Shen T; Hui YR; Gu XC; Li RS
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):337-9. PubMed ID: 12941184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.
    Yu W; Sun X; Tang H; Tao Y; Dai Z
    Leuk Lymphoma; 2010 Jun; 51(6):1098-107. PubMed ID: 20536348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
    Guo JQ; Lian J; Glassman A; Talpaz M; Kantarjian H; Deisseroth AB; Arlinghaus RB
    Am J Clin Pathol; 1996 Oct; 106(4):442-8. PubMed ID: 8853030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction of 293pT2-P210 cell line enables expression of bcr/abl to be regulated by Tet-off inducing-expression-system].
    Huang WR; Lu ZZ; Wang LS; Wang H; Duan HF; Li QF; Gao CJ; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):224-8. PubMed ID: 17493320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-step discrimination of BCR/ABL
    Luo N; Xia Q; Zhang L; Zhang Y; Huang L; Zhang Y; Zhao J; Ding S; Cheng W
    Anal Chim Acta; 2019 Aug; 1067():129-136. PubMed ID: 31047144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of P210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences.
    Lewalle P; Martiat P
    Leuk Lymphoma; 1993; 11 Suppl 1():139-43. PubMed ID: 8251887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of transcriptional targets associated with the expression of p210 Bcr-Abl.
    Hickey FB; Cotter TG
    Eur J Haematol; 2006 May; 76(5):369-83. PubMed ID: 16494625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
    Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
    Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic myelogenous leukemia expressing two bcr-abl chimeric mRNA; a case report].
    Hashimoto S; Hiyoshi M; Hino M; Yamane T; Ota T; Koh KR; Tagawa S; Tatsumi N
    Rinsho Ketsueki; 1997 Jan; 38(1):72-4. PubMed ID: 9028165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo].
    Zhu YF; Wang YZ; Meng FY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1090-4. PubMed ID: 23114125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.